Archives: Agenda

• Understanding how the new UK framework is working in practice 6 months after implementation
• Identifying key operational changes, including approvals, consent, and trial setup
• Clarifying how sponsors can take advantage of faster pathways while staying compliant

Reserved for NIHR

Update from COMBINE “all-in-one” Pilot Exploring the coordinated assessment of combined study applications

• Learnings and experience from the pilot phase 1
• Framework of the pilot phase 2 and experiences so far

• Understanding how multiple systems increase burden for sites and study teams
• Identifying where technology slows down rather than supports trial delivery
• Simplifying workflows across platforms to improve adoption and efficiency
• Reducing friction without removing valuable data and insights

Moderator

Kamil Sitarz, Chief Operating Officer, Ryvu Therapeutics

• Explore what becomes possible when clinical data and decisions are connected across study design, country strategy, feasibility, and site selection
• Hear the Novo Nordisk + H1 story and how the organizations are working together toward a more connected clinical development ecosystem
• Learn how to move beyond fragmented systems, spreadsheets, and data sources toward a trusted foundation that helps teams make faster, more informed decisions
• Discover how connecting sponsor intelligence with site-level insights and feedback can strengthen feasibility and site selection while reducing disconnects across the trial lifecycle
• See why connected, mastered data is critical to unlocking the potential of AI in clinical development, and why the future requires more than another point solution

• Identify where Nordic R&D innovation is concentrating across therapy areas, development stages and emerging modalities
• Compare Denmark, Sweden, Finland and Norway to reveal distinct innovation profiles and emerging areas of specialisation
• Benchmark Nordic R&D against the global pipeline to identify where the region is over-indexing and which therapeutic areas and emerging modalities could shape the next wave of drug development